Just over a year ago, there was a major breakthrough in Parkinson’s disease (PD) research – the discovery of a tool that could detect abnormal alpha-synuclein protein in the spinal fluid of people living with PD even before onset of symptoms. In our recent “Parkinson’s Science POV” podcast episode, MJFF’s Maggie McGuire Kuhl, vice president of research engagement leads a discussion with Brian Fiske, PhD and Mark Frasier, PhD, MJFF co-chief science officers. They discuss the ways the biomarker discovery helps reveal connections with other brain diseases and holds the promise to make clinical trials cheaper, faster and more effective. Listen now: https://bit.ly/3LoS0FK
Kevin McKeon
1mo
It’s wonderful to see progress happening in the search for a cure. Never give up.
Soy paciente con EP he escrito muchas veces a la fundación MJFF pero no encuentro respuesta, deseo formar parte de sus pacientes para investigación, vivo en Bogotá Colombia. email André[email protected] que oportunidad tengo?
Paul Zimmet
1mo
@
Transforming Parkinson’s Disease Treatment. Track Record as Innovator. Experience at FDA and DARPA. "Worthy 100" (2023).
1moThe advances in diagnostics are important and impressive. Let’s also put that focus into developing novel therapeutics. With the limited benefit of current therapies, let’s look for (and support) new ways to treat the disease. Read my weekly newsletter at ParkinsonsDisease.blog https://parkinsonsdisease.blog Parkinson's Foundation The Michael J. Fox Foundation for Parkinson's Research #parkinsons #parkinsonsdisease